Investigation into Optimal Administration of Gadolinium Ethoxybenzyl Diethylenetriamine Pentaacetic Acid and Appropriate Timing of Arterial Phase of Enhanced Liver Magnetic Resonance Imaging for Hepatocellular Carcinoma

Investigation into Optimal Administration of Gadolinium Ethoxybenzyl Diethylenetriamine Pentaacetic Acid and Appropriate Timing of Arterial Phase of Enhanced Liver Magnetic Resonance Imaging for Hepatocellular Carcinoma - Investigation into Optimal Administration of Ga-EOB-DTPA and Appropriate Timing of Arterial Phase of Enhanced Liver Magnetic Resonance Imaging for HCC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004103

Enrollment

150

Registered

2010-08-30

Start date

2010-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Duration:the day of MRI examination. All fluid (EOB + saline):0.5ml per 1kg body weight, using EOB undiluted. Duration:the day of MRI examination. All fluid (EOB + saline):0.5ml per 1kg body weight,

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who were diagnosed as hepatocellular carcinoma by contrast enhanced CT and was scheduled for surgical resection. 2) Patients who can undergo EOB-MRI within one month from contrast enhanced CT. 3) Patients who announced voluntary consent through their writing after a full explanation of the study and a enough understanding. 4) Patients over 20 years old at the time of obtaining informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients with lesions that are received prior RFA or TAE treatment. 2) Patients with a history of hypersensitivity to gadolinium-based contrast agent or this test drug. 3) Patients who have asthma. 4) Patients with severe kidney disease. (eGFR<30mL/min/1.73square meter or serum Cr>1.5mg/dl) 5) Patients during pregnancy or potential pregnancy. 6) Patients who are lactating women. 7) Patients who have advanced nyctophobia cabin.

Design outcomes

Primary

Measure	Time frame
We make time intensity curves of tumor, parenchyma of liver and aorta in each way of administration and also investigate these data.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026